News

A little-known government entity within the National Institutes of Health (NIH) is helping to lead U.S. efforts to speed up the development of therapies for some 7,000 rare diseases. The Office of Rare Diseases Research (ORDR), headquartered in Bethesda, Maryland, was established in 1993 within the NIH Office of the…

In honor of Bleeding Disorder Awareness Month, celebrated in March, CVS Health is donating more than $260,000 to national and local hemophilia and bleeding disorder programs across the United States. Although there’s no exact number of how many people are now living…

The five adults with hemophilia A who died while using Hemlibra (emicizumab-kxwh) to treat their disease did not die of causes related to the treatment, manufacturer Genentech said in a statement. “In each of these cases, the assessment of the treating physician or investigator was that the cause of death was unrelated to…

A delivery method using nanotubes with a spear-like shape may open new avenues for safer, faster, and more cost-effective gene therapies for several genetic diseases, including hemophilia, according to a study. The study, “Precision-Guided Nanospears for Targeted and High-Throughput Intracellular Gene Delivery,” was recently published in the…

BioMarin Pharmaceutical has won an award for getting its new gene therapy facility in Novato, California, operational ahead of schedule. The International Society for Pharmaceutical Engineering (ISPE) award was for project execution. It was part of the society’s 2018 Facility of the Year honors. BioMarin took only a year from the time…

Hemlibra (emicizumab) is an effective and less costly therapy for hemophilia A patients who have substances in their blood that prevent clotting factor therapies from working as well as they should, according to a therapy rating organization. The Institute for Clinical and Economic Review (ICER) updated an initial report on Hemlibra…